Worth Asset Management LLC Has $828,000 Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Worth Asset Management LLC trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 62.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,963 shares of the biopharmaceutical company’s stock after selling 15,111 shares during the period. Worth Asset Management LLC’s holdings in Gilead Sciences were worth $828,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in GILD. Range Financial Group LLC increased its position in shares of Gilead Sciences by 285.3% during the fourth quarter. Range Financial Group LLC now owns 10,626 shares of the biopharmaceutical company’s stock valued at $982,000 after purchasing an additional 7,868 shares during the period. First County Bank CT boosted its stake in Gilead Sciences by 2.9% during the fourth quarter. First County Bank CT now owns 23,760 shares of the biopharmaceutical company’s stock worth $2,195,000 after buying an additional 680 shares in the last quarter. Spartan Planning & Wealth Management bought a new stake in Gilead Sciences in the 4th quarter valued at $230,000. Diversified Trust Co boosted its position in shares of Gilead Sciences by 3.0% during the 4th quarter. Diversified Trust Co now owns 34,455 shares of the biopharmaceutical company’s stock valued at $3,183,000 after acquiring an additional 1,019 shares in the last quarter. Finally, Oliver Luxxe Assets LLC acquired a new position in Gilead Sciences in the fourth quarter worth about $4,463,000. Institutional investors own 83.67% of the company’s stock.

Insider Activity

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the sale, the director now owns 8,920 shares in the company, valued at approximately $815,198.80. The trade was a 43.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Andrew D. Dickinson sold 8,500 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $91.96, for a total value of $781,660.00. Following the transaction, the chief financial officer now directly owns 132,373 shares of the company’s stock, valued at approximately $12,173,021.08. This trade represents a 6.03 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 453,734 shares of company stock worth $41,902,086 over the last quarter. 0.16% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

GILD has been the topic of a number of recent research reports. Mizuho lifted their price objective on Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Robert W. Baird lifted their price objective on Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a report on Thursday, November 7th. Truist Financial upped their target price on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a report on Friday, November 8th. Oppenheimer lifted their price target on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. Finally, Citigroup initiated coverage on shares of Gilead Sciences in a report on Thursday, November 14th. They set a “buy” rating and a $125.00 price objective for the company. Twelve research analysts have rated the stock with a hold rating, twelve have issued a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $96.43.

Gilead Sciences Trading Down 1.2 %

GILD traded down $1.06 during mid-day trading on Wednesday, hitting $89.57. The stock had a trading volume of 2,300,665 shares, compared to its average volume of 4,499,835. The stock’s fifty day simple moving average is $91.91 and its 200-day simple moving average is $82.98. The firm has a market capitalization of $111.63 billion, a price-to-earnings ratio of 995.22, a price-to-earnings-growth ratio of 2.24 and a beta of 0.18. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.90. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter last year, the business posted $2.29 EPS. The firm’s revenue was up 7.0% compared to the same quarter last year. As a group, research analysts forecast that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 3.44%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s payout ratio is currently 3,422.22%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.